[{"id":"f6e4b9e7-700b-461e-a552-fa0f4e734931","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441046","created_at":"2022-07-01T21:55:28.776Z","updated_at":"2024-07-02T16:36:07.751Z","phase":"Phase 1","brief_title":"Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05441046","lead_sponsor":"GeneScience Pharmaceuticals Co., Ltd.","biomarkers":" IL6 • TNFA • CXCL8 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Jin Beixin (firsekibart)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-07-06"}]